Luma buy fleshes out SpectraScience's cancer detection portfolio:
This article was originally published in Clinica
Executive Summary
San Diego, California-based SpectraScience has expanded its reach in the cancer detection market with the acquisition of Luma Imaging, a developer of optical noninvasive cervical cancer diagnostic technology. Luma's FDA-approved cervical imaging system is designed as an easy-to-use adjunctive device to conventional colposcopy to improve the detection of cervical cancer. Clinical trials have shown that the product can detect over 25% more precancerous cells in the cervix than colposcopy alone. Luma's technology complements SpectraScience's WavSTAT system, which is also optics-based and noninvasive. The WavSTAT is approved for use in detecting precancer and cancer in the colon. SpectraScience is currently evaluating its technology for detecting precancers in the throat.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.